Kiniksa Pharmaceuticals International PLC
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Kiniksa Pharmaceuticals International PLC
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
/ 
Frequently asked questions
To buy Kiniksa Pharmaceuticals International PLC stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Kiniksa Pharmaceuticals International PLC by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Kiniksa Pharmaceuticals International PLC is KNSA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Kiniksa Pharmaceuticals International PLC has its primary listing on NASDAQ. You can trade Kiniksa Pharmaceuticals International PLC with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Kiniksa Pharmaceuticals International PLC is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Kiniksa Pharmaceuticals International PLC as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Kiniksa Pharmaceuticals International PLC.